HRP20130036T1 - Domene i epitopi meningokoknog proteina nmb1870 - Google Patents
Domene i epitopi meningokoknog proteina nmb1870 Download PDFInfo
- Publication number
- HRP20130036T1 HRP20130036T1 HRP20130036TT HRP20130036T HRP20130036T1 HR P20130036 T1 HRP20130036 T1 HR P20130036T1 HR P20130036T T HRP20130036T T HR P20130036TT HR P20130036 T HRP20130036 T HR P20130036T HR P20130036 T1 HRP20130036 T1 HR P20130036T1
- Authority
- HR
- Croatia
- Prior art keywords
- amino acid
- sequence
- seq
- acid sequence
- main chain
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 28
- 150000001413 amino acids Chemical class 0.000 claims 13
- 238000000034 method Methods 0.000 claims 13
- 229920001184 polypeptide Polymers 0.000 claims 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims 8
- 239000012634 fragment Substances 0.000 claims 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical group C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 5
- 101100446533 Neisseria meningitidis serogroup B (strain MC58) fhbP gene Proteins 0.000 claims 3
- 241000588650 Neisseria meningitidis Species 0.000 claims 1
- 108700018753 Neisseria porin Proteins 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000002163 immunogen Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Description
DOMENE I EPITIPI MENINGOKOKNOG PROTEINA NMB 1870
Claims (24)
1. Postupak za proizvodnju himerične NMB1870 aminokiselinske sekvence, naznačen time da sadrži sljedeće korake: (a) poravnavanje prve NMB1870 aminokiselinske sekvence s drugom NMB1870 aminokiselinskom sekvencom, pri čemu se prva i druga sekvenca razlikuju i iz različitih su NMB 1870 obitelji, kako bi se dobio par poravnatih sekvenci, (b) odabiranje dijela prve aminokiselinske sekvence, počevši od aminokiseline a1 navedene prve aminokiselinske sekvence, sa završetkom kod aminokiseline bi navedene prve aminokiselinske sekvence, gdje navedeni dio predstavlja sekvencu površinske petlje (c) odabiranje dijela druge aminokiselinske sekvence, počevši od aminokiseline a2 navedene druge aminokiselinske sekvence, sa završetkom kod aminokiseline bi navedene druge aminokiselinske sekvence, pri čemu je navedeni dio sekvenca površinske petlje, i gdje su rezidui a1 i a2 i b1 i b2 poravnati u par poravnatih sekvenci; i (d) zamjena navedenog dijela prve aminokiselinske sekvence sa spomenutim dijelom druge aminokiselinske sekvence, čime se pruža himerična NMB 1870 aminokiselinska sekvenca, u kojoj aminokiselinske sekvence čine sekvencu glavnog lanca, s osam dijelova, i sedam površinskih petlji, po jedna između svakog dijela sekvence glavnog lanca.
2. Postupak prema zahtjevu 1, naznačen time daje prva sekvenca sekvenca obitelji 1 NMB 1870.
3. Postupak prema zahtjevu 2, naznačen time da je prva sekvenca SEQ ID NO: 1.
4. Postupak prema zahtjevu 3, naznačen time da su površinske petlje u SEQ ID NO: 1: (1) aminokiseline 134-141; (2) aminokiseline 162-168; (3) aminokiseline 181-182; (4) aminokiselina 197: (5) aminokiseline 219-223; (6) aminokiseline 234-236; (7) aminokiseline 261-267.
5. Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time da je druga sekvenca SEQ ID NO: 2 ili SEQ ID NO: 3.
6. Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time da su izabrani dijelovi dužine najmanje 3 aminokiselina.
7. Postupak prema bilo kojem zahtjevu 1-6, naznačen time da dio sadrži površinsku petlju (1).
8. Postupak prema bilo kojem zahtjevu 1-6, naznačen time da dio sadrži površinsku petlju (2).
9. Postupak prema bilo kojem zahtjevu 1-5, naznačen time da dio sadrži površinsku petlju (3).
10. Postupak prema bilo kojem zahtjevu 1-5, naznačen time da dio sadrži površinsku petlju (4).
11. Postupak prema bilo kojem zahtjevu 1-6, naznačen time da dio sadrži površinsku petlju (5).
12. Postupak prema bilo kojem zahtjevu 1-6, naznačen time da dio sadrži površinsku petlju (6).
13. Postupak prema bilo kojem zahtjevu 1-6, naznačen time da dio sadrži površinsku petlju (7).
14. Himerični polipeplid koji sadrži himeričnu NMB 1870 aminokiselinsku sekvencu, naznačen time da se može dobiti pomoću postupka bilo kojeg zahtjeva od 1 do 5.
15. Polipeptid koji sadrži aminokiselinsku sekvencu:
-B1-L1-L2-B2-B3-L3-B4-L4-L5-B5-B6-L6-B7-L7-B8- naznačen time da:
(a) svaki od navedenih B,, B2, B3, B4, B5, B6, B7 i B8 je: (i) fragment sekvence SEQ ID NO: 1; i (ii) aminokiselinska sekvenca s najmanje 95% identiteta s fragmentom spomenutim u (i) i/ili sadrži fragment od najmanje 6 najbližih aminokiselina iz fragmenta spomenutog u (i);
(b) svaki od spomenutih L1, L2, L3, L4, L5, L6 i L7 je: (iii) fragment sekvenci SEQ ID NO: 1, SF.Q ID NO: 2 i/ili SEQ ID NO: 3, pod uvjetom da najmanje jedan od navedenih L1, L2, L3, L4, L5, L6 i L7 nije fragment SEQ ID NO: 1,
i da su B1 do B8 definirani kako slijedi:
[image]
i da su L1 do L7 definirani kako slijedi:
[image]
16. Polipeptid koji sadrži aminokiselinsku sekvencu koja ima ukupni identitet sa sekvencom SEQ ID NO: 1 od najmanje 80%, naznačen time da: je identitet navedene aminokiselinske sekvence sa sekvencom SEQ ID NO: 1 veći od 80% u regijama glavnog lanca SEQ ID NO: 1; i da je identitet sekvence navedene aminokiselinske sekvence sa SEQ ID NO: 1 manji od 80% u regijama petlji SEQ ID NO: 1, u kojima aminokiselinska sekvenca sadrži glavni lanac s osam regija glavnog lanca, kao i sedam regija petlji, po jednu između svakog dijela sekvence glavnog lanca.
17. Polipeptid koji sadrži aminokiselinsku sekvencu koja ima ukupni identitet sa sekvencom SEQ ID NO: 2 od najmanje 80%, naznačen time da: je identitet sekvence navedene aminokiselinske sekvence sa SEQ ID NO: 2 veći od 80% u regijama glavnog lanca SEQ ID NO: 2; i identitet sekvence navedene aminokiselinske sekvence sa SEQ ID NO: 2 manji od 80% u regijama petlji sekvence SEQ ID NO: 2, u kojima aminokiselinska sekvenca sadrži glavni lanac s osam regija glavnog lanca i sedam regija petlje, po jednu između svakog dijela sekvence glavnog lanca.
18. Polipeptid koji sadrži aminokiselinsku sekvencu koja ima ukupan identitet sa sekvencom SEQ ID NO: 3 od najmanje 80%, naznačen time da: je identitet sekvence navedene aminokiselinske sekvence sa SEQ ID NO: 3 veći od 80% u regijama glavnog lanca sekvence SEQ ID NO: 3; i identitet spomenute aminokiselinske sekvence sa SEQ ID NO: 3 manji od 80% u regijama petlji SEQ ID NO: 3, u kojima aminokiselinska sekvenca sadrži glavni lanac, s osam regija glavnog lanca i sedam regija petlje, po jednu između svakog dijela sekvence glavnog lanca.
19. Nukleinska kiselina, naznačena time da kodira polipeptid iz bilo kojeg zahtjeva od 14 do 18.
20. Imunogeni sastav, naznačen time da sadrži polipeptid iz bilo kojeg zahtjeva od 14 do 18.
21. Sastav prema zahtjevu 20, naznačen time da sadrži i aluminijsku sol kao adjuvans.
22. Sastav prema zahtjevu 20 ili 21, naznačen time da sadrži i meningokokni PorA protein.
23. Sastav prema zahtjevu 20 ili 21, naznačen time da sadrži i preparat vezikule vanjske membrane N.meningitidis.
24. Polipeptid prema bilo kojem zahtjevu od 14 do 18, naznačen time da je za upotrebu kao lijek.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0419408A GB0419408D0 (en) | 2004-09-01 | 2004-09-01 | 741 chimeric polypeptides |
| PCT/IB2005/002968 WO2006024954A2 (en) | 2004-09-01 | 2005-09-01 | Domains and epitopes of meningococcal protein nmb1870 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20130036T1 true HRP20130036T1 (hr) | 2013-02-28 |
Family
ID=33155851
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20130036TT HRP20130036T1 (hr) | 2004-09-01 | 2013-01-17 | Domene i epitopi meningokoknog proteina nmb1870 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20090285845A1 (hr) |
| EP (1) | EP1784419B1 (hr) |
| JP (2) | JP4827196B2 (hr) |
| CN (1) | CN101031584B (hr) |
| AU (1) | AU2005278904B2 (hr) |
| BR (1) | BRPI0514829A (hr) |
| CA (1) | CA2578014A1 (hr) |
| CY (1) | CY1113554T1 (hr) |
| DK (1) | DK1784419T3 (hr) |
| ES (1) | ES2396422T3 (hr) |
| GB (1) | GB0419408D0 (hr) |
| HR (1) | HRP20130036T1 (hr) |
| MX (1) | MX2007002094A (hr) |
| NZ (1) | NZ553229A (hr) |
| PL (1) | PL1784419T3 (hr) |
| PT (1) | PT1784419E (hr) |
| RS (1) | RS52634B (hr) |
| RU (1) | RU2375374C2 (hr) |
| SI (1) | SI1784419T1 (hr) |
| WO (1) | WO2006024954A2 (hr) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2261339B1 (en) | 1998-05-01 | 2017-03-22 | GlaxoSmithKline Biologicals SA | Neisseria meningitidis antigens and compositions |
| US20070026021A1 (en) * | 1998-05-01 | 2007-02-01 | Chiron S.R.I. | Neisseria meningitidis antigens and compositions |
| WO2001031019A2 (en) | 1999-10-29 | 2001-05-03 | Chiron Spa | Neisserial antigenic peptides |
| NZ545647A (en) * | 1999-05-19 | 2008-02-29 | Chiron Srl | Combination neisserial compositions |
| PT1248647E (pt) * | 2000-01-17 | 2010-11-18 | Novartis Vaccines & Diagnostics Srl | Vacina de vesícula da membrana externa (omv) compreendendo proteínas de membrana externa de n. meningitidis do serogrupo b |
| JP4846160B2 (ja) | 2000-02-28 | 2011-12-28 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル | ナイセリア属のタンパク質のハイブリッド発現 |
| GB0118249D0 (en) | 2001-07-26 | 2001-09-19 | Chiron Spa | Histidine vaccines |
| GB0121591D0 (en) | 2001-09-06 | 2001-10-24 | Chiron Spa | Hybrid and tandem expression of neisserial proteins |
| MX339524B (es) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
| DK1549338T3 (da) * | 2002-10-11 | 2011-03-28 | Novartis Vaccines & Diagnostic | Polypeptidvacciner til bred beskyttelse mod hypervirulente meningokok-afstamningslinier |
| GB0227346D0 (en) * | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
| GB0408977D0 (en) * | 2004-04-22 | 2004-05-26 | Chiron Srl | Immunising against meningococcal serogroup Y using proteins |
| AU2013201318B2 (en) * | 2005-11-25 | 2015-11-19 | Glaxosmithkline Biologicals Sa | Chimeric, hybrid and tandem polypeptides of meningococcal NMB 1870 |
| GB0524066D0 (en) | 2005-11-25 | 2006-01-04 | Chiron Srl | 741 ii |
| AR064642A1 (es) | 2006-12-22 | 2009-04-15 | Wyeth Corp | Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi |
| CN102356089B (zh) | 2008-02-21 | 2014-02-19 | 诺华股份有限公司 | 脑膜炎球菌fHBP多肽 |
| US9511131B2 (en) | 2008-03-10 | 2016-12-06 | Children's Hospital & Research Center Oakland | Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use |
| CA2726512A1 (en) * | 2008-06-09 | 2009-12-17 | Novartis Ag | Antibodies against neisserial factor h binding protein |
| SI2411048T1 (sl) | 2009-03-24 | 2020-08-31 | Glaxosmithkline Biologicals Sa | Meningokokni faktor H vezavni protein uporabljen kot adjuvans |
| JP5668049B2 (ja) * | 2009-03-24 | 2015-02-12 | ノバルティス アーゲー | 髄膜炎菌ｈ因子結合タンパク質および肺炎球菌糖結合体の組み合わせ |
| CN102711814A (zh) * | 2009-04-30 | 2012-10-03 | 奥克兰儿童医院及研究中心 | 一种嵌合h因子结合蛋白(fhbp)及其使用方法 |
| US8858958B2 (en) | 2009-08-27 | 2014-10-14 | Novartis Ag | Adjuvant comprising aluminum, oligonucleotide and polycation |
| EP2470204B1 (en) | 2009-08-27 | 2015-12-16 | GlaxoSmithKline Biologicals SA | Hybrid polypeptides including meningococcal fhbp sequences |
| EP2483390A2 (en) | 2009-09-30 | 2012-08-08 | Novartis AG | Expression of meningococcal fhbp polypeptides |
| AU2010310985B2 (en) | 2009-10-27 | 2014-11-06 | Glaxosmithkline Biologicals S.A. | Modified meningococcal fHBP polypeptides |
| TR201802933T4 (tr) * | 2010-03-30 | 2018-03-21 | Childrens Hospital & Res Center At Oakland | Özellikleri değiştirilmiş faktör h bağlama proteinleri (fhbp) ve bunların kullanım yöntemi. |
| EP2585106A1 (en) | 2010-06-25 | 2013-05-01 | Novartis AG | Combinations of meningococcal factor h binding proteins |
| ES2850973T3 (es) | 2010-08-23 | 2021-09-01 | Wyeth Llc | Formulaciones estables de antígenos rLP2086 de Neisseria meningitidis |
| ES2728282T3 (es) | 2010-09-10 | 2019-10-23 | Wyeth Llc | Variantes no lipidadas de antígenos ORF2086 de Neisseria meningitidis |
| WO2013098589A1 (en) | 2011-12-29 | 2013-07-04 | Novartis Ag | Adjuvanted combinations of meningococcal factor h binding proteins |
| JP2015517089A (ja) * | 2012-03-08 | 2015-06-18 | ノバルティス アーゲー | タンパク質ベースの髄膜炎菌ワクチンのためのインビトロ有効性アッセイ |
| SA115360586B1 (ar) | 2012-03-09 | 2017-04-12 | فايزر انك | تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها |
| JP5925342B2 (ja) | 2012-03-09 | 2016-05-25 | ファイザー・インク | 髄膜炎菌（Ｎｅｉｓｓｅｒｉａｍｅｎｉｎｇｉｔｉｄｉｓ）組成物およびその方法 |
| EP2861247B1 (en) | 2012-06-14 | 2020-12-09 | GlaxoSmithKline Biologicals SA | Vaccines for serogroup x meningococcus |
| JP2015524418A (ja) | 2012-07-27 | 2015-08-24 | アンスティテュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 血管内皮細胞への髄膜炎菌の線毛媒介接着の受容体としてのｃｄ１４７ |
| US9802987B2 (en) | 2013-03-08 | 2017-10-31 | Pfizer Inc. | Immunogenic fusion polypeptides |
| JP2016527278A (ja) | 2013-08-02 | 2016-09-08 | チルドレンズ ホスピタル アンド リサーチ センター オークランド | 天然に生じないｈ因子結合タンパク質（ｆｈｂｐ）及びその使用の方法 |
| BR112016004463A2 (pt) | 2013-09-08 | 2017-10-17 | Pfizer | composições de neisseria meningitidis e métodos das mesmas |
| BR112016019735A2 (pt) | 2014-02-28 | 2017-10-17 | Glaxosmithkline Biologicals Sa | fhbp, polipeptídeo, plasmídeo ou outro ácido nucleico, célula hospedeira, vesículas de membrana, e, composição imunogênica |
| CA2954729C (en) * | 2014-07-17 | 2023-08-22 | Glaxosmithkline Biologicals S.A. | Meningococcus vaccines |
| JP2017522320A (ja) | 2014-07-17 | 2017-08-10 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 修飾された髄膜炎菌ｆｈｂｐポリペプチド |
| RU2714248C2 (ru) | 2014-07-23 | 2020-02-13 | Чилдрен'З Хоспитал Энд Рисёрч Сентер Эт Окленд | Варианты фактор н-связывающего белка и способы их применения |
| US10888611B2 (en) | 2015-02-19 | 2021-01-12 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
| US11066453B2 (en) | 2015-05-18 | 2021-07-20 | Biomvis Srl | Immunogenic compositions containing bacterial outer membrane vesicles and therapeutic uses thereof |
| GB201614687D0 (en) * | 2016-08-31 | 2016-10-12 | Univ Oxford Innovation Ltd | fHbp scaffold |
| IL303108B1 (en) | 2017-01-31 | 2024-03-01 | Pfizer | NEISSERIA MENINGITIDIS preparations and methods therefor |
| EP3536706A1 (en) | 2018-03-09 | 2019-09-11 | BiOMVis Srl | Fusion proteins for the outer membrane vesicle (omv) delivery of heterologous polypeptides and immunogenic compositions thereof |
| EP3725371A1 (en) | 2019-04-18 | 2020-10-21 | BiOMVis Srl | Method for the production of outer membrane vesicles and immunogenic compositions thereof |
| US20240016916A1 (en) | 2020-05-15 | 2024-01-18 | Biomvis S.R.L. | Bacterial outer membrane vesicles carrying coronavirus polypeptides, method of preparation, compositions and use thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070026021A1 (en) * | 1998-05-01 | 2007-02-01 | Chiron S.R.I. | Neisseria meningitidis antigens and compositions |
| EP2261339B1 (en) | 1998-05-01 | 2017-03-22 | GlaxoSmithKline Biologicals SA | Neisseria meningitidis antigens and compositions |
| NZ545647A (en) * | 1999-05-19 | 2008-02-29 | Chiron Srl | Combination neisserial compositions |
| PT1248647E (pt) * | 2000-01-17 | 2010-11-18 | Novartis Vaccines & Diagnostics Srl | Vacina de vesícula da membrana externa (omv) compreendendo proteínas de membrana externa de n. meningitidis do serogrupo b |
| JP4846160B2 (ja) * | 2000-02-28 | 2011-12-28 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル | ナイセリア属のタンパク質のハイブリッド発現 |
| GB0118249D0 (en) * | 2001-07-26 | 2001-09-19 | Chiron Spa | Histidine vaccines |
| GB0121591D0 (en) * | 2001-09-06 | 2001-10-24 | Chiron Spa | Hybrid and tandem expression of neisserial proteins |
| MX339524B (es) * | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
| US20060240045A1 (en) * | 2002-08-02 | 2006-10-26 | Francois-Xavier Berthet | Neisserial vaccine compositions comprising a combination of antigens |
| US7785608B2 (en) * | 2002-08-30 | 2010-08-31 | Wyeth Holdings Corporation | Immunogenic compositions for the prevention and treatment of meningococcal disease |
| DK1549338T3 (da) * | 2002-10-11 | 2011-03-28 | Novartis Vaccines & Diagnostic | Polypeptidvacciner til bred beskyttelse mod hypervirulente meningokok-afstamningslinier |
| GB0227346D0 (en) * | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
| EP2289546A3 (en) * | 2003-01-30 | 2011-03-30 | Novartis Vaccines and Diagnostics S.r.l. | Injectable vaccines against multiple meningococcal serogroups |
| EP1961426B1 (en) * | 2003-10-02 | 2011-04-27 | Novartis Vaccines and Diagnostics S.r.l. | Combined meningitis vaccines |
| GB0524066D0 (en) * | 2005-11-25 | 2006-01-04 | Chiron Srl | 741 ii |
| TW200806315A (en) * | 2006-04-26 | 2008-02-01 | Wyeth Corp | Novel formulations which stabilize and inhibit precipitation of immunogenic compositions |
| SI2411048T1 (sl) * | 2009-03-24 | 2020-08-31 | Glaxosmithkline Biologicals Sa | Meningokokni faktor H vezavni protein uporabljen kot adjuvans |
-
2004
- 2004-09-01 GB GB0419408A patent/GB0419408D0/en not_active Ceased
-
2005
- 2005-09-01 SI SI200531651T patent/SI1784419T1/sl unknown
- 2005-09-01 US US11/661,665 patent/US20090285845A1/en not_active Abandoned
- 2005-09-01 RS RS20130004A patent/RS52634B/en unknown
- 2005-09-01 AU AU2005278904A patent/AU2005278904B2/en not_active Ceased
- 2005-09-01 CN CN2005800293251A patent/CN101031584B/zh not_active Expired - Fee Related
- 2005-09-01 PT PT05786178T patent/PT1784419E/pt unknown
- 2005-09-01 NZ NZ553229A patent/NZ553229A/en not_active IP Right Cessation
- 2005-09-01 WO PCT/IB2005/002968 patent/WO2006024954A2/en active Application Filing
- 2005-09-01 EP EP20050786178 patent/EP1784419B1/en active Active
- 2005-09-01 DK DK05786178T patent/DK1784419T3/da active
- 2005-09-01 BR BRPI0514829-4A patent/BRPI0514829A/pt not_active IP Right Cessation
- 2005-09-01 JP JP2007529041A patent/JP4827196B2/ja not_active Expired - Fee Related
- 2005-09-01 MX MX2007002094A patent/MX2007002094A/es active IP Right Grant
- 2005-09-01 PL PL05786178T patent/PL1784419T3/pl unknown
- 2005-09-01 RU RU2007111700A patent/RU2375374C2/ru not_active IP Right Cessation
- 2005-09-01 CA CA 2578014 patent/CA2578014A1/en not_active Abandoned
- 2005-09-01 ES ES05786178T patent/ES2396422T3/es active Active
-
2011
- 2011-05-19 JP JP2011112884A patent/JP2011168611A/ja not_active Withdrawn
-
2013
- 2013-01-17 HR HRP20130036TT patent/HRP20130036T1/hr unknown
- 2013-01-23 CY CY20131100064T patent/CY1113554T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2007111700A (ru) | 2008-10-10 |
| SI1784419T1 (sl) | 2013-02-28 |
| WO2006024954A3 (en) | 2006-08-24 |
| RS52634B (en) | 2013-06-28 |
| WO2006024954A2 (en) | 2006-03-09 |
| ES2396422T3 (es) | 2013-02-21 |
| EP1784419A2 (en) | 2007-05-16 |
| CN101031584B (zh) | 2012-09-05 |
| CA2578014A1 (en) | 2006-03-09 |
| MX2007002094A (es) | 2007-04-24 |
| BRPI0514829A (pt) | 2008-06-24 |
| US20090285845A1 (en) | 2009-11-19 |
| PT1784419E (pt) | 2013-01-15 |
| EP1784419B1 (en) | 2012-10-24 |
| CN101031584A (zh) | 2007-09-05 |
| GB0419408D0 (en) | 2004-10-06 |
| DK1784419T3 (da) | 2013-02-04 |
| JP2011168611A (ja) | 2011-09-01 |
| JP4827196B2 (ja) | 2011-11-30 |
| WO2006024954A9 (en) | 2012-03-15 |
| JP2008511306A (ja) | 2008-04-17 |
| PL1784419T3 (pl) | 2013-03-29 |
| AU2005278904B2 (en) | 2012-02-09 |
| CY1113554T1 (el) | 2016-06-22 |
| RU2375374C2 (ru) | 2009-12-10 |
| NZ553229A (en) | 2010-07-30 |
| AU2005278904A1 (en) | 2006-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20130036T1 (hr) | Domene i epitopi meningokoknog proteina nmb1870 | |
| JP2008538183A5 (hr) | ||
| EP2356996B1 (en) | Treatment for Alzheimer's disease | |
| NL300899I2 (nl) | Neisseira meningitidis serogroep B recombinant gelipideerd fHbp subfamilie A05 eiwit en Neisseira meningitidis serogroep B recombinant gelipideerd fHbp subfamilie B01 eiwit | |
| NZ604818A (en) | Variants of activin iib receptor polypeptides and uses thereof | |
| JP2012501959A5 (hr) | ||
| JP2008530245A5 (hr) | ||
| JP2013543497A5 (hr) | ||
| JP2008521795A5 (hr) | ||
| JP2011530599A5 (hr) | ||
| RU2015142996A (ru) | Пептидная вакцина для предупреждения и иммунотерапии деменции альцгеймеровского типа | |
| JP2010162023A5 (hr) | ||
| HRP20220756T1 (hr) | Proteinski pripravci rsv f i postupci za izradu istih | |
| AR064642A1 (es) | Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi | |
| JP2010513506A5 (hr) | ||
| CA2563185A1 (en) | Sustained release formulations of a peptide or protein and a purified gallic acid ester | |
| JP2009500298A5 (hr) | ||
| DE60035419D1 (de) | Antigene peptide aus neisseria | |
| DE602004001727D1 (de) | Verfahren zur herstellung cyclischer peptide | |
| JP2008539164A5 (hr) | ||
| JP2004531242A5 (hr) | ||
| RU2016111115A (ru) | Стабильные полипептиды, связывающиеся с с5 комплемента человека | |
| RU2004116914A (ru) | Очищенные оболочечные белки вируса гепатита с для диагностического и терапевтического применения | |
| CA2901346C (en) | Chimeric vaccine antigens against hepatitis c virus | |
| JP2013517224A5 (hr) |